LGT Fund Management Co Ltd. Has $1.68 Million Stake in Medpace Holdings, Inc. $MEDP

LGT Fund Management Co Ltd. lowered its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 66.0% in the first quarter, Holdings Channel reports. The firm owned 3,500 shares of the company’s stock after selling 6,800 shares during the quarter. LGT Fund Management Co Ltd.’s holdings in Medpace were worth $1,681,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dorsey Wright & Associates acquired a new position in Medpace during the third quarter valued at approximately $5,082,000. Allspring Global Investments Holdings LLC increased its position in shares of Medpace by 164.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock worth $2,086,000 after purchasing an additional 2,274 shares during the last quarter. Capital Impact Advisors LLC increased its position in shares of Medpace by 31.7% during the 3rd quarter. Capital Impact Advisors LLC now owns 26,995 shares of the company’s stock worth $13,880,000 after purchasing an additional 6,495 shares during the last quarter. Aquatic Capital Management LLC raised its stake in shares of Medpace by 244.5% during the 3rd quarter. Aquatic Capital Management LLC now owns 24,158 shares of the company’s stock worth $12,421,000 after purchasing an additional 17,146 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Medpace during the 4th quarter worth approximately $4,084,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MEDP. Royal Bank Of Canada decreased their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. BMO Capital Markets cut their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $469.17.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 20.50% of the stock is currently owned by corporate insiders.

Medpace Price Performance

Shares of MEDP opened at $538.23 on Monday. The firm has a market capitalization of $15.37 billion, a PE ratio of 33.83, a PEG ratio of 2.73 and a beta of 1.15. The company’s 50-day moving average is $467.24 and its 200-day moving average is $495.50. Medpace Holdings, Inc. has a fifty-two week low of $306.70 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. During the same quarter in the previous year, the firm posted $3.67 EPS. Medpace’s revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.